You are here

Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Schmittingheide 20-32, Munster, 48155 Denmark
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Secure diagnosis of rheumatoid arthritis

- Older than 18 years

- Two consecutive plain radiographs of the hands and feet with a time interval of 12 to
36 months are available. The radiographs are recorded 2003 or later and are in
accordance with a defined X-ray protocol.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who receive Anakinra, Rituximab or Abatacept

NCT00929357
Pfizer
Completed
Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
NCT00413699
All Genders
18+
Years
Multiple Sites
Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment
A Retrospective Evaluation of the Radiographic Efficacy of Different Conventional Systemic Therapies and Biologics in Patients With Rheumatoid Arthritis in Routine Practice.
This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs) or Biologics and have two existing, consecutive radiographs (x-ray images) of hand and feet taken as part of routine treatment monitoring within a time interval of 12 to 36 months.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
200
Rheumatoid Arthritis
Drug: DMARDs or Biologics
  • 1
    DMARDs
    Intervention: Drug: DMARDs or Biologics
  • 2
    Biologics
    Intervention: Drug: DMARDs or Biologics
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
156
June 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Secure diagnosis of rheumatoid arthritis
  • Older than 18 years
  • Two consecutive plain radiographs of the hands and feet with a time interval of 12 to 36 months are available. The radiographs are recorded 2003 or later and are in accordance with a defined X-ray protocol.

Exclusion Criteria:

- Patients who receive Anakinra, Rituximab or Abatacept

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00929357
0881X1-4617
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Wyeth
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer
August 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now